UroGen Pharma Ltd Reiterated FY23 Revenue $76M-$86M Vs $80.74M Est
Portfolio Pulse from Benzinga Newsdesk
UroGen Pharma Ltd has reiterated its FY23 revenue forecast to be between $76M and $86M, which is slightly below the estimated $80.74M.
August 10, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
UroGen Pharma's reiterated FY23 revenue forecast is slightly below the estimated $80.74M, which may impact investor sentiment.
UroGen Pharma's FY23 revenue forecast is slightly below the market estimate. This could lead to negative investor sentiment as it indicates that the company may not meet market expectations, potentially leading to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100